Effects of Losartan on Insulin Resistance in Patients With Heart Failure

Heart Failure Clinical Trial

Official title:

Losartan Improved Insulin Resistance and Decreased Inflammatory Cytokines in Patients With Chronic Heart Failure Treated With Angiotensin Converting Enzyme Inhibitors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00663377
• Other study ID #: #656
• Status: Completed
• Phase: Phase 4
• First received: April 18, 2008
• Last updated: April 18, 2008
• Start date: April 2006
• Est. completion date: March 2007

Study information

• Verified date: April 2008
• Source: Tottori University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of losartan, an ARB, on glucose metabolism and inflammatory cytokines in CHF patients treated with ACE inhibitors.

Description:

Chronic heart failure (CHF) is associated with marked insulin resistance, characterized by both fasting and stimulated hyperinsulinemia. Furthermore, insulin resistance is a predictor of CHF and associated with more severe disease and a worse prognosis in patients with CHF. In CHF patients, therefore, insulin resistance is not merely a function of adiposity and may have implications in the pathophysiology of CHF disease progression. Angiotensin II negatively modulates insulin-mediated actions by regulating multiple levels of the insulin signaling cascade such as the insulin receptor, IRS, and PI3-kinase. Furthermore, both ACE inhibitors and angiotensin II receptor blockers (ARB) improve glycemic status not only in patients with type II diabetes but also in patients with hypertension and the metabolic syndrome. On the other hand, it is well known that some cytokines, such as TNF-α, are involved with pathophysiology of insulin resistance and CHF. However, it is still unclear whether the ARB improves insulin resistance in CHF patients already treated with ACE inhibitors and whether there is the relationship between insulin resistance and inflammatory cytokines in CHF patients already treated with ACE inhibitors. Therefore, the purpose of this study is to evaluate the effects of losartan, an ARB, on glucose metabolism and inflammatory cytokines in CHF patients treated with ACE inhibitors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: March 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• chronic stable heart failure

Exclusion Criteria:

• renal dysfunction or under treatment with antidiabetic agents

Related Conditions & MeSH terms

• Heart Failure
• Insulin Resistance

Intervention

Drug:
• losartan
losartan 50-100mg for 16 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tottori University Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	insulin resistance		16 weeks
Secondary	inflammatory cytokines		16 weeks